OptimizeRx (NASDAQ:OPRX) Raised to Strong-Buy at Wall Street Zen

OptimizeRx (NASDAQ:OPRX) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Other equities research analysts have also issued reports about the company. Citizens Jmp increased their price target on OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of OptimizeRx in a report on Wednesday, October 8th. Roth Capital restated a “buy” rating on shares of OptimizeRx in a research note on Friday, August 8th. Stifel Nicolaus upped their price target on shares of OptimizeRx from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Finally, UBS Group set a $23.00 price objective on shares of OptimizeRx in a report on Friday, October 10th. Nine research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, OptimizeRx has an average rating of “Moderate Buy” and a consensus price target of $14.45.

OptimizeRx Price Performance

Shares of OPRX traded down $3.29 during trading hours on Friday, hitting $15.65. The stock had a trading volume of 1,013,794 shares, compared to its average volume of 372,301. The stock has a market capitalization of $290.54 million, a price-to-earnings ratio of -28.98 and a beta of 1.24. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The company’s fifty day moving average is $18.87 and its two-hundred day moving average is $15.10. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $22.25.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. The firm had revenue of $26.07 million for the quarter, compared to analyst estimates of $23.83 million. OptimizeRx had a negative net margin of 9.42% and a positive return on equity of 4.50%. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. On average, analysts anticipate that OptimizeRx will post -0.33 EPS for the current year.

Insider Activity

In related news, Director Patrick D. Spangler sold 11,120 shares of the business’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $17.49, for a total transaction of $194,488.80. Following the completion of the sale, the director directly owned 44,215 shares of the company’s stock, valued at $773,320.35. The trade was a 20.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Stephen L. Silvestro sold 1,620 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $18.75, for a total transaction of $30,375.00. Following the completion of the transaction, the chief executive officer owned 188,916 shares in the company, valued at $3,542,175. This represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 5.60% of the company’s stock.

Institutional Trading of OptimizeRx

Several institutional investors and hedge funds have recently made changes to their positions in OPRX. Nisa Investment Advisors LLC boosted its position in shares of OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after purchasing an additional 1,818 shares during the last quarter. Quantbot Technologies LP bought a new position in OptimizeRx during the second quarter worth about $44,000. BNP Paribas Financial Markets boosted its holdings in OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares during the last quarter. USA Financial Formulas acquired a new position in shares of OptimizeRx during the 3rd quarter worth about $131,000. Finally, Wesbanco Bank Inc. bought a new stake in shares of OptimizeRx in the 3rd quarter valued at about $205,000. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.